Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646225 | 0.77 | MEN1 (0.43) | ACHEPOLA1 | |
| SCHEMBL29442689 | 0.77 | KDM4E (0.48) | ACHEPOLA1 | |
| SCHEMBL1506593 | 0.77 | KDM4E (0.48) | ACHEPOLA1 | |
| SCHEMBL29442662 | 0.77 | MEN1 (0.43) | ACHEPOLA1 | |
| SCHEMBL20869626 | 0.77 | DRD2 (0.44) | HRH3FYNHDAC6 | |
| Bromide SCHEMBL20854668 | 0.76 | DRD2 (0.43) | HRH3FYNHDAC6 | |
| SCHEMBL19604782 | 0.73 | ACHE (0.39) | ACHEPOLA1 | |
| SCHEMBL2820210 | 0.73 | HRH3 (0.54) | HRH3CYP2D6 | |
| SCHEMBL19604788 | 0.73 | ACHE (0.39) | ACHEPOLA1 | |
| SCHEMBL2824273 | 0.72 | HRH3 (0.56) | HRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007735-B1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20080039444-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039444-A1 | COMPOUNDS | CMA1, MRGPRX2, HRH2 | HRH3 16/4885CYP2D6 177/4885FYN 2328/4885 |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | HRH2, HRH3, HRH4 | HRH3 2/4885CYP2D6 398/4885FYN 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.